Published in
American Society for Microbiology, Journal of Virology, 19(95), 2021
DOI: 10.1128/jvi.00685-21
Links
Tools
Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants
Journal article published in 2021 by
Mathieu Ferrari 
,
Leila Mekkaoui,
F. Tudor Ilca,
Zulaikha Akbar,
Reyisa Bughda,
Katarina Lamb,
Katarzyna Ward,
Farhaan Parekh,
Rajeev Karattil,
Christopher Allen ,
Philip Wu,
Vania Baldan,
Giada Mattiuzzo,
Emma M. Bentley,
Yasuhiro Takeuchi
and other authors.
,
Leila Mekkaoui,
F. Tudor Ilca,
Zulaikha Akbar,
Reyisa Bughda,
Katarina Lamb,
Katarzyna Ward,
Farhaan Parekh,
Rajeev Karattil,
Christopher Allen ,
Philip Wu,
Vania Baldan,
Giada Mattiuzzo,
Emma M. Bentley,
Yasuhiro Takeuchi
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
Mutational drift of SARS-CoV-2 risks rendering both therapeutics and vaccines less effective. Receptor decoy strategies utilizing soluble human ACE2 may overcome the risk of viral mutational escape since mutations disrupting viral interaction with the ACE2 decoy will by necessity decrease virulence, thereby preventing meaningful escape.